Quantifying mortality burden in patients with cancer due to COVID-19 in the US: A national cross-sectional analysis.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
08 2023
Historique:
revised: 06 07 2023
received: 11 04 2023
accepted: 09 07 2023
medline: 15 9 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

There is limited information on the impact of certain social factors on mortality outcomes in patients with cancer and COVID-19 on a national scale. This study aims to characterize excess mortality and analyze a subset of sociodemographic trends in COVID-19 and cancer mortality. Patients with cancer listed on their death certificates from 2018 to 2021 and patients with COVID-19 and cancer listed on multiple cause of death certificates from the CDC Wide-Ranging Online Data for Epidemiologic Research database from March 2020 to December 2021 were included. Age-adjusted mortality rates (AAMR) per 1,000,000 population were compared across race/ethnicity groups, sex, and census regions. Crude mortality rates were compared across different age groups and regions based on urbanization status. Average AAMR in patients with COVID-19 and cancer was 41.7 in 2020 and 56.7 in 2021. Mortality rates in patients with cancer and COVID-19 were significantly higher in certain populations. Targeted interventions are necessary to improve outcomes.

Identifiants

pubmed: 37537960
doi: 10.1002/cam4.6364
pmc: PMC10501232
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17413-17417

Informations de copyright

© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Int J Environ Res Public Health. 2022 Sep 30;19(19):
pubmed: 36231769
Vital Health Stat 2. 2014 Apr;(166):1-73
pubmed: 24776070
Curr Oncol Rep. 2022 Oct;24(10):1219-1235
pubmed: 35622263
Trans R Soc Trop Med Hyg. 2022 Sep 10;116(9):767-797
pubmed: 35276734
J Gen Intern Med. 2023 Apr;38(5):1344-1347
pubmed: 36750506
J Cancer Biol. 2021;2(1):25-32
pubmed: 34447972
JAMA Oncol. 2022 Jan 1;8(1):69-78
pubmed: 34709356
Cancer Rep (Hoboken). 2021 Oct;4(5):e1388
pubmed: 34014037
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
JAMA Oncol. 2022 Nov 1;8(11):1696-1698
pubmed: 36173612
Cancer Med. 2023 Aug;12(16):17413-17417
pubmed: 37537960

Auteurs

Bhaghyasree Jambunathan (B)

The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Jacob Lang (J)

The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Malik Mays (M)

The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Obi Ekwenna (O)

Department of Urology and Transplantation, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH